ReNeuron to automate stem cell stroke therapy production for Phase III trial – BioPharma-Reporter.com
BioPharma-Reporter.com |
ReNeuron to automate stem cell stroke therapy production for Phase III trial
BioPharma-Reporter.com ReNeuron will automate processing of its stem cell-based stroke therapy ahead of planned Phase III trials using a system acquired from Sartorius Stedim Biotech (SSB) subsidiary, TAP Biosystems. |
